Efficacies of capecitabine combined with irinotecan or rh-endostatin for treatment of oxaliplatin-resistant patients with advanced colorectal cancer

Chinese Journal of Cancer Biotherapy

Volumn 16, Issue 2, 2009, Pages 175-180

  Zhuang, Chao Ping ^a   Cai, Gao Yang ^a   Li, Ting Han ^a   Wang, Yong Quan ^a   Chen, Wei Rong ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Advanced stage; Capecitabine; Colorectal neoplasms; Irinotecan; rh endostatin

Indexed keywords

CAPECITABINE; ENDOSTAR; ENDOSTATIN; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; SKIN PIGMENTATION; THROMBOCYTOPENIA;

EID: 77953452895     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2009.02.015     Document Type: Article

References (19)

1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol. 2000, 18 (16): 2938-2947.
2. Chinese source.
3. Chinese source.
4. Chinese source.
5. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials [J]. Br J Cancer,2004, 90(6): 1190-1197.
6. Park SH, Bang SM, Cho EK, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectall cancer [J]. Oncology, 2004, 66(5): 353-357.
7. Ahn JB, Jung KH, Park YS, et al. Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (AC-RC) [J]. J Clin Oncol, 2005, 23 (16): 3714-3720.
8. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan [J]. Clin Cancer Res. 2005, 11(3): 1226-1236.
9. Quintela-Fandino M, Gravalos C, Gonzalez E et al. Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer [J]. Anticancer Drugs. 2005, 16(1): 31-38.
10. Heudel P, Romestaing P, Barbet N, et al. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial [J]. Clin Oncol (R Coll Radiol), 2008, 20(5): 369-374.
11. Moehler M, Sprinzl MF, Abdelfattah M, et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients [J]. World J Gastroenterol. 2009,15(4): 449-456.
12. Chinese source.
13. Chinese source.
14. Chinese source.
15. Li B, Wu X, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin [J]. Biochemistry, 2004, 43(9): 2550-2557.
16. Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine [J]. Anticancer Drugs, 2005,16(5): 551-557.
17. Chinese source.
18. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular re-growth in tumors after reversal of VEGF inhibition [J]. J Clin Invest, 2006, 116(10): 2610-2621.
19. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer [J]. Recent Results Cancer Res, 2005, 165: 250-259.